Semaglutide
Sold under the brand names; Wegovy (by Novo Nordisk) & Ozempic and approved for use (depending on the brand) for weight management, blood glucose management and cardiovascular risk reduction.
Semaglutide binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.1
Also available in pill form (since ???).
Key Usage Considerations
Oral vs Injectable Treatment
Body Composition
Exercise is better for this.
Side Effects
Ending Treatment
References
Metadata
Created:
Last Updated: 2026-01-24
-
https://bnf.nice.org.uk/drugs/semaglutide/ - 2024-12-04 ↩